Malignant Melanoma

  • Junichi Hiratsuka
  • Hiroshi Fukuda


In 1972, an experimental study on boron neutron capture therapy (BNCT) for malignant melanoma was initiated by Mishima and his colleagues. They first proposed employing BNCT for malignant melanomas, utilizing the specific melanin synthesis activity of melanoma cells. For that purpose, 10B-para-boronophenylalanine (BPA) was reevaluated by his group (Kobe University group). Clinical investigations of BNCT for melanoma were started for patients with cutaneous melanomas using BPA and a thermal neutron beam and using an epithermal beam to treat patients with brain metastases of malignant melanoma. Five groups have carried out BNCT of melanoma in the world: at the Massachusetts Institute of Technology (MIT) for cutaneous melanoma and for intracerebral melanoma (Harvard/MIT group), at the high flux reactor in Petten for brain metastases of melanoma (Petten/Essen group), at RA-6 reactor in Argentina for cutaneous melanoma (Argentina group), and at KUR and JRR-4 in Japan for mucosal melanomas of the head and neck. The local responses and survival of patients with cutaneous and mucosal malignant melanomas treated with BNCT are summarized in this chapter.


Brain Metastasis Maximum Tolerable Dose Cutaneous Melanoma Boron Concentration Boron Neutron Capture Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mishima Y (1973) Neutron capture treatment of malignant melanoma using 10B-chlorpromazine compound. In: McGovern VJ, Russell P (eds) Pigment Cell, vol 1, Mechanisms in Pigmentation. S. Karger, Basel, pp 215–221Google Scholar
  2. 2.
    Fukuda H, Kobayashi T, Matsuzawa T et al (1987) RBE of a thermal neutron beam and the 10B(n, α)7Li reaction on cultured B-16 melanoma cells. Int J Radiat Biol 51:167–175CrossRefGoogle Scholar
  3. 3.
    Yoshino K, Suzuki K, Mori Y et al (1989) Improvement of solubility of p-boronophenylalanine by complex formation with monosaccarides. Strahlenther Onkol 165:127–129PubMedGoogle Scholar
  4. 4.
    Hiratsuka J, Kono M, Mishima Y (1989) RBEs of thermal neutron capture therapy and 10B(n, α)7Li reaction on melanoma-bearing hamsters. Pigment Cell Res 2:352–355PubMedCrossRefGoogle Scholar
  5. 5.
    Mishima Y, Ichihashi M, Hatta S et al (1989) New thermal neutron capture therapy for malignant melanoma: melanogenesis-seeking 10B molecule-melanoma cell interaction from in vitro to first clinical trial. Pigment Cell Res 2:226–234PubMedCrossRefGoogle Scholar
  6. 6.
    Mishima Y, Honda C, Ichihashi M et al (1989) Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B-compound. Lancet II:388–389CrossRefGoogle Scholar
  7. 7.
    Hiratsuka J, Fukuda H, Kobayashi T et al (1991) The relative biological effectiveness of 10B-neutron capture therapy for early skin reaction in the hamster. Radiat Res 128:186–191PubMedCrossRefGoogle Scholar
  8. 8.
    Fukuda H, Hiratsuka J, Honda C et al (1994) Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat Res 138:435–442PubMedCrossRefGoogle Scholar
  9. 9.
    Mishima Y (1996) Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities—Melanoma as prototype Cancer. In: Mishima Y (ed) Neutron Capture Therapy. Plenum Press, New York, pp 1–26Google Scholar
  10. 10.
    Yoshino K, Mishima Y, Kimura M et al (1997) Capture of p-boronophenylalanine in malignant melanoma cells by complex formation with melanin monomers, DOPA, DHI and DHICA. BPA trapping mechanism. In: Larsson B, Crawford J, Weinreich R (eds) Advances in Neutron Capture Therapy. Elsevier Science, Amsterdam, pp 234–238Google Scholar
  11. 11.
    Fukuda H, Honda C, Wadabayashi N et al (1999) Pharmacokinetics of 10B-p-boronophenylalanine in tumors, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res 9:75–83PubMedCrossRefGoogle Scholar
  12. 12.
    Fukuda H, Hiratsuka J, Kobayashi T et al (2003) Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med 26:78–84CrossRefGoogle Scholar
  13. 13.
    Madoc-Jones H, Zamenhof R, Solares G et al (1996) A phase-Idose escalation trial of boron neutron capture therapy for subjects with metastatic subcutaneous melanoma of the extremities. In: Mishima Y (ed) Cancer Neutron Capture Therapy. Plenum Press, New York, pp 707–716Google Scholar
  14. 14.
    Busse PM, Zamenhof R, Madoc-Jones H et al (1997) Clinical follow-up of patients with melanoma of the extremity treated in a phase I boron neutron capture therapy protocol. In: Larson B, Crawford J, Weinreich R (editors) Advances in Neutron Capture Therapy, Volume I: 60–64Google Scholar
  15. 15.
    Palmer MR, Goorley JT, Kiger WS III et al (2002) Treatment planning and dosimetry for the Harvard-MIT PhaseIIclinical trial of cranial neutron capture therapy. Int J Radiat Oncol Biol Phys 53:1361–1379PubMedCrossRefGoogle Scholar
  16. 16.
    Sauerwein W, Zurlo A (2002) The EORTC boron neutron capture therapy (BNCT) group: achievements and future projects. Eur J Cancer 38:S31–S34PubMedCrossRefGoogle Scholar
  17. 17.
    Wittig A, Sauerwein W, Moss R, et al. Early phaseIstudy o BNCT in metastatic malignant melanoma using the boron carrier BPA (EORTC protocol 11011). In advances in Neutron Capture Therapy 2006 (Y. Nakagawa, T Kobayashi and H Fukuda Ed.) 284–287. (Proceedings of ICNCT-12), 2006Google Scholar
  18. 18.
    Gonzales SJ, Bonomi MR, Santacruz GA et al (2004) First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome. Appl Radiat Isot 61:1101–1105CrossRefGoogle Scholar
  19. 19.
    Roth BM, Bonomi MR, Gonzalez SJ, et al (2006) BNCT clinical trials of skin melanoma patients in Argentina. Proceedings of ICNCT-12. Edited by Nakagawa Y, Kobayashi T and Fukuda H: 14–17Google Scholar
  20. 20.
    Morita N, Hiratsuka J, Kuwabara C, et al. (2006) Successful BNCT for patients with cutaneous and mucosal melanomas: Report of 4 cases. Proceedings of ICNCT-12. Edited by Nakagawa Y, Kobayashi T and Fukuda H: 18–20Google Scholar
  21. 21.
    Kirkwood JM, Strawderman MH, Ernstoff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7–17PubMedGoogle Scholar
  22. 22.
    Geara FB, Ang KK (1996) Radiation therapy for malignant melanoma. Surg Clin North Am 76(6):1383–1398PubMedCrossRefGoogle Scholar
  23. 23.
    Harwood AR, Cummings BJ (1982) Radiotherapy for mucosal melanomas. Int J Radiat Oncol Biol Phys 8:1121PubMedCrossRefGoogle Scholar
  24. 24.
    Vtyurin BM, MedvedevVS AnikinVA et al (1994) Neutron branchytherapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 28:703–709PubMedCrossRefGoogle Scholar
  25. 25.
    Umebayashi S, Uyeno K, Tsujii H et al (1995) Proton radiotherapy for malignant melanoma of the skin. Dermatology 190:210–213PubMedCrossRefGoogle Scholar
  26. 26.
    Coderre JA, Glass JD, Fairchild RG et al (1990) Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res 50:138–141PubMedGoogle Scholar
  27. 27.
    Papaspyrou M, Feinendegen LE, Müller-Gärtner H-W (1994) Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 54(24):6311–6314PubMedGoogle Scholar
  28. 28.
    Wittig A, Sauerwein WA, Coderre JA (2000) Mechanisms of transport of p-Borono-phenylalanine through the cell membrane in vitro. Radiat Res 153(2):173–180PubMedCrossRefGoogle Scholar
  29. 29.
    Miyatake S, Kawabata S, Kajimoto Y et al (2005) Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103:1000–1009PubMedCrossRefGoogle Scholar
  30. 30.
    Kato I, Ono K, Sakurai Y et al (2004) Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61:1069–1073PubMedCrossRefGoogle Scholar
  31. 31.
    Aihara T, Hiratsuka J, Morita N et al (2006) First clinical case of boron neutron capture therapy for head and neck malignancy. Head Neck 28:850–855PubMedCrossRefGoogle Scholar
  32. 32.
    Coderre JA, Morris GM (1999) Review; The radiation biology of boron neutron capture therapy. Radiat Res 151:1–18PubMedCrossRefGoogle Scholar
  33. 33.
    Coderre JA, Hopewell JW, Turcotte JC et al (2004) Tolerance of normal human brain to boron neutron capture therapy. Appl Radiat Isot 61:1083–1087PubMedCrossRefGoogle Scholar
  34. 34.
    Johanson CR, Harwood AR, Cummings BJ et al (1983) 0-7-21 Radiotherapy in nodular melanoma. Cancer 51:226–232PubMedCrossRefGoogle Scholar
  35. 35.
    Ono K, Masunaga S, Kinashi Y, et al. (2006) Neutron irradiation under continuous BPA injection for solving the problem of heterogenous distribution of BPA. Proceedings of ICNCT-12. Edited by Nakagawa Y, Kobayashi T and Fukuda H: 27–30Google Scholar
  36. 36.
    Kankaanranta L, Seppala T, Koivunoro H et al (2007) Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys 69:475–482PubMedCrossRefGoogle Scholar
  37. 37.
    Ono K, Masunaga S, Suzuki M et al (1999) The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice. Int J Radiat Oncol Biol Phys 43:431–436PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Radiation OncologyKawasaki Medical SchoolOkayamaJapan
  2. 2.Department of Nuclear Medicine and RadiologyInstitute of Development, Aging and Cancer, Tohoku UniversitySendaiJapan

Personalised recommendations